Our study establishes FCGR2A as a pivotal interface between metabolic inflammation and ccRCC progression, reconciling the paradoxical association of obesity with both increased cancer risk and enhanced immunotherapy responses (8). The gene discussed is FCGR2A; the disease is obesity due to melanocortin 4 receptor deficiency.